NeuroSense Therapeutics Ltd. has announced the completion of its pre-New Drug Submission (pre-NDS) meeting with Health Canada regarding the potential early approval of its drug, PrimeC, for the treatment of ALS. The company engaged in a constructive dialogue with Health Canada and is now in the process of finalizing the official meeting minutes. Following this, NeuroSense will receive formal notification about its eligibility to proceed with an NDS under the expedited Notice of Compliance with Conditions (NOC/c) pathway. The company expressed optimism about the positive tone of the meeting and anticipates providing a detailed update once the official notification is received. No other organizations were mentioned in relation to this regulatory review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.